Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05987449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05987449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 21, 2023
Completion date
December 11, 2033
Enrollment
60 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a